Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada
We identified an influenza B isolate harboring a Gly407Ser neuraminidase substitution in an immunocompromised patient in Canada before antiviral therapy. This mutation mediated reduced susceptibility to oseltamivir, zanamivir, and peramivir, most likely by preventing interaction with the catalytic A...
Main Authors: | Yacine Abed, Clément Fage, Patrick Lagüe, Julie Carbonneau, Jesse Papenburg, Donald C. Vinh, Guy Boivin |
---|---|
Format: | Article |
Language: | English |
Published: |
Centers for Disease Control and Prevention
2019-04-01
|
Series: | Emerging Infectious Diseases |
Subjects: | |
Online Access: | https://wwwnc.cdc.gov/eid/article/25/4/18-1554_article |
Similar Items
-
In Vitro Characterization of Multidrug-Resistant Influenza A(H1N1)pdm09 Viruses Carrying a Dual Neuraminidase Mutation Isolated from Immunocompromised Patients
by: Emi Takashita, et al.
Published: (2020-09-01) -
NEURAMINIDASE INHIBITORS — THE GOLD STANDARD OF ANTIVIRAL INFLUENZA A THERAPY
by: V. V. TSVETKOV, et al.
Published: (2017-05-01) -
Neuraminidase Inhibitors: Development and Validation of a Procedure for <i>In Vitro</i> Determination of the Inhibitory Effect
by: N. M. Faustova, et al.
Published: (2023-03-01) -
Etiotropic therapy and chemoprophylaxis of influenza with neuraminidase inhibitors
by: T. G. Zubkova, et al.
Published: (2020-01-01) -
Discovery of oseltamivir-based novel PROTACs as degraders targeting neuraminidase to combat H1N1 influenza virus
by: Zhichao Xu, et al.
Published: (2022-06-01)